Answers are grounded in this paper and cite their sources.
Purpose of Review Biosimilars are antibody-based therapies that are highly similar to originator biologic molecules. The unique, streamlined authorization process for biosimilars has resulted in the approval and relatively rapid availability of numerous biosimilar agents for the treatment of Crohn’s disease and ulcerative colitis. In this narrative review, we provide a detailed overview of the evidence, evaluating the efficacy and safety of biosimilars in the management of inflammatory bowel disease. Recent Findings Multiple clinical trials have examined the use of infliximab biosimilars in the treatment of inflammatory bowel disease, including PROSIT-BIO, PLANET-CD, and NOR-SWITCH, collectively demonstrating similar effectiveness and safety outcomes between infliximab biosimilars and originator infliximab. Data from VOLTAIRE-CD evaluated an adalimumab biosimilar in the treatment of Crohn’s disease and found no significant difference in efficacy or safety compared to the reference biologic. Ustekinumab biosimilar clinical trial data is primarily limited to the plaque psoriasis patient population, with multiple studies demonstrating no major differences between biosimilar and originator in key clinical endpoints. Summary The available evidence supports the use of biosimilars as effective and safe alternatives to originator therapies. While clinical trials have examined infliximab and adalimumab biosimilars in patients with inflammatory bowel disease, there is a paucity of clinical trials evaluating ustekinumab in the Crohn’s disease and ulcerative colitis populations, instead relying on extrapolation in other inflammatory conditions.
No takes yet. Share an insight, caveat, or question.
Weber et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: